{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:57:33Z","timestamp":1765727853298},"reference-count":34,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijdvl.ijdvl_840_18","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T07:15:39Z","timestamp":1569309339000},"page":"674","source":"Crossref","is-referenced-by-count":8,"title":["Wonder drug for worms: A review of three decades of ivermectin use in dermatology"],"prefix":"10.25259","volume":"85","author":[{"given":"Saravanan","family":"Gowtham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaliaperumal","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.267726-1","first-page":"13","volume-title":"Ivermectin, 'wonder drug' from Japan: The human use perspective","author":"Crump","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"key-10.4103\/0378-6323.267726-2","unstructured":"Discovery of Ivermectin Mectizan \u2013 American Chemical Society. Available from: https:\/\/www.acs.org\/content\/acs\/en\/education\/whatischemistry\/landmarks\/ivermectin-mectizan.html. [Last accessed on 2018 Sep 3]."},{"key":"key-10.4103\/0378-6323.267726-3","doi-asserted-by":"crossref","unstructured":"Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: Pharmacology and application in dermatology. Int J Dermatol 2005;44:981-8.","DOI":"10.1111\/j.1365-4632.2004.02253.x"},{"key":"key-10.4103\/0378-6323.267726-4","unstructured":"Ivermectin. Pubchem. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6321424. [Last accessed on 2018 Aug 17]"},{"key":"key-10.4103\/0378-6323.267726-5","first-page":"42","volume-title":"The pharmacokinetics and interactions of ivermectin in humans \u2013 A mini-review","author":"Gonz\u00e1lez","year":"2008","journal-title":"AAPS J"},{"key":"key-10.4103\/0378-6323.267726-6","doi-asserted-by":"crossref","unstructured":"Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: Pharmacology and therapeutic applications. Int J Basic Clin Pharmacol 2012;1:132-9.","DOI":"10.5455\/2319-2003.ijbcp002712"},{"key":"key-10.4103\/0378-6323.267726-7","first-page":"1833","volume-title":"Ivermectin and its target molecules: Shared and unique modulation mechanisms of ion channels and receptors by ivermectin","author":"Chen","year":"2018","journal-title":"J Physiol"},{"key":"key-10.4103\/0378-6323.267726-8","first-page":"211","volume-title":"Pediculosis and scabies: A treatment update","author":"Gunning","year":"2013","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/0378-6323.267726-9","first-page":"11","volume-title":"The efficacy of topical and oral ivermectin in the treatment of human scabies","author":"Panahi","year":"2015","journal-title":"Ann Parasitol"},{"key":"key-10.4103\/0378-6323.267726-10","first-page":"605","volume-title":"Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies","author":"Chhaiya","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"http:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.267726-11","first-page":"340","volume-title":"Crusted scabies","author":"Karthikeyan","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"http:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.267726-12","first-page":"8962685","volume-title":"Management and treatment of human lice","author":"Sangar\u00e9","year":"2016","journal-title":"Biomed Res Int"},{"key":"key-10.4103\/0378-6323.267726-13","first-page":"896","volume-title":"Oral ivermectin versus malathion lotion for difficult-to-treat head lice","author":"Chosidow","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.267726-14","first-page":"1425","volume-title":"European guideline for the management of pediculosis pubis","author":"Salavastru","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.267726-15","first-page":"60","volume-title":"Human demodex mite: The versatile mite of dermatological importance","author":"Rather","year":"2014","journal-title":"Indian J Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0378-6323.267726-16","first-page":"1151","volume-title":"The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: A network meta-analysis","author":"Siddiqui","year":"2016","journal-title":"Springerplus"},{"key":"key-10.4103\/0378-6323.267726-17","first-page":"79","volume-title":"Myiasis","author":"Francesconi","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"key-10.4103\/0378-6323.267726-18","unstructured":"Prevention C-C for DC and. CDC \u2013 Lymphatic Filariasis \u2013 Treatment; 2017. Available from: https:\/\/www.cdc.gov\/parasites\/lymphaticfilariasis\/treatment.html. [Last accessed on 2018 Mar 16]"},{"key":"key-10.4103\/0378-6323.267726-19","first-page":"252","volume-title":"Cutaneous larva migrans","author":"Karthikeyan","year":"2002","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"http:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.267726-20","first-page":"1246","volume-title":"Treatment of cutaneous larva migrans","author":"Van","year":"1998","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.267726-21","first-page":"e288","volume-title":"Strongyloides stercoralis hyperinfection presenting as acute respiratory failure and gram-negative sepsis in a patient with astrocytoma","author":"Shorman","year":"2009","journal-title":"Int J Infect Dis"},{"key":"key-10.4103\/0378-6323.267726-22","first-page":"140","volume-title":"Loiasis: New epidemiologic insights and proposed treatment strategy","author":"Boussinesq","year":"2012","journal-title":"J Travel Med"},{"key":"key-10.4103\/0378-6323.267726-23","unstructured":"Ivermectin.pdf. Available from: http:\/\/news.nursesfornurses.com.au\/test\/wp-content\/uploads\/2015\/02\/ivermectin.pdf. [ Last accessed on 2018 Aug 17]."},{"key":"key-10.4103\/0378-6323.267726-24","first-page":"514","volume-title":"Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg?","author":"Wilkins","year":"2018","journal-title":"Arch Dis Child"},{"key":"key-10.4103\/0378-6323.267726-25","first-page":"196","volume-title":"Strategies in infectious disease prevention and management among US-bound refugee children","author":"Dang","year":"2014","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"key-10.4103\/0378-6323.267726-26","first-page":"217","volume-title":"Synergistic activity of antibiotics combined with ivermectin to kill body lice","author":"Sangar\u00e9","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0378-6323.267726-27","doi-asserted-by":"crossref","unstructured":"Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2003;2(Suppl. 1):S4.","DOI":"10.1186\/1475-2883-2-S1-S4"},{"key":"key-10.4103\/0378-6323.267726-28","first-page":"156","volume-title":"Adverse reactions following annual ivermectin treatment of onchocerciasis in Nigeria","author":"Oyibo","year":"2003","journal-title":"Int J Infect Dis"},{"key":"key-10.4103\/0378-6323.267726-29","first-page":"77","volume-title":"Does dexamethasone suppress the Mazzotti reaction in patients with onchocerciasis?","author":"Stingl","year":"1988","journal-title":"Acta Trop"},{"key":"key-10.4103\/0378-6323.267726-30","first-page":"667","volume-title":"Inflammatory reactions in onchocerciasis: A report on current knowledge and recommendations for further study","author":"Henson","year":"1979","journal-title":"Bull World Health Organ"},{"key":"key-10.4103\/0378-6323.267726-31","first-page":"459","volume-title":"Onchocerciasis: The role of wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment","author":"Tamarozzi","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"key-10.4103\/0378-6323.267726-32","doi-asserted-by":"crossref","unstructured":"Edwards G. Ivermectin: Does P-glycoprotein play a role in neurotoxicity? Filaria J 2003;2 Suppl 1:S8.","DOI":"10.1186\/1475-2883-2-S1-S8"},{"key":"key-10.4103\/0378-6323.267726-33","first-page":"382","volume-title":"Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?","author":"Chandler","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0378-6323.267726-34","first-page":"1293","volume-title":"Tackling scabies: Novel agents for a neglected disease","author":"Gopinath","year":"2018","journal-title":"Int J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:42:14Z","timestamp":1611916934000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/wonder-drug-for-worms-a-review-of-three-decades-of-ivermectin-use-in-dermatology\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"alternative-id":["267726"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_840_18","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}